ICP 057
Alternative Names: ICP-057Latest Information Update: 28 Nov 2022
Price :
$50 *
At a glance
- Originator InnoCare Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for research development in Autoimmune-disorders in China
- 09 Oct 2018 InnoCare Pharma has global intellectual property rights for ICP 057 (InnoCare Pharma pipeline, October 2018)
- 09 Oct 2018 Early research in Autoimmune disorders in China (unspecified route) (InnoCare Pharma pipeline, October 2018)